Bimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A and IL-17F, has been recently approved for the treatment of moderate to severe psoriasis in adults, promising a PASI 90 and PASI 100 score in 4 weeks and maintenance of effectiveness up to 52 weeks, with a good safety profile [192]. Here, IL17A is linked to psoriasis.